Recent progress in immunotherapy: Anti-cancer vaccines, emerging clinical data

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5T4 VACCINE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANTINEOPLASTIC AGENT; BCG VACCINE; BLP25 VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; DOCETAXEL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; LENALIDOMIDE; PEPTIDE VACCINE; PLACEBO; TROVAX; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; HISTORY OF MEDICINE; HUMAN; LOW DRUG DOSE; LUNG CANCER; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT; VACCINATION; ARTICLE; IMMUNOLOGY; NEOPLASM;

CANCER VACCINES; HUMANS; NEOPLASMS;

EID: 53449087943     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn441     Document Type: Conference Paper

References (20)

1. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 2004; 363: 594-599.
2. Uyl-de Groot CA, Vermorken JB, Hanna MG Jr et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: A prospective study of medical and economic benefits. Vaccine 2005; 23: 2379-2387.
3. Hsueh EC, Essner R, Foshag LJ et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20: 4549-4554.
4. Morton DL, Hsueh EC, Essner R et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002; 236: 438-449.
5. Finke LH, Wentworth K, Blumenstein B et al. Lessons from randomized phase III studies with active cancer immunotherapies: Outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; 25 (Suppl 2): B97-B109.
6. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: Current status and future directions. Vaccine 2007; 25 (Suppl 2): B4-16.
7. Lee KH, Panelli MC, Kim CJ et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998; 161: 4183-4194.
8. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.
9. Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007: B89-96.
10. Hrouda D, Todryk SM, Perry MJ et al. Allogeneic whole-tumor cell vaccination in the rat model of prostate cancer. BJU Int 2000; 86: 742-748.
11. Michael A, Ball G, Quatan N et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11: 4469-4478.
12. Copier J, Ward S, Dalgleish A. Tumor cell cancer vaccines; regulatory and commercial development. Vaccine 2007; In press.
13. Arlen PM, Gulley JL, Todd N et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005; 174: 539-546.
14. O'Brien ME, Anderson H, Kaukel E et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann Oncol 2004; 15: 906-914.
15. Stanford JL, Stanford CA, O'Brien ME et al. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008; 44: 224-227.
16. Sangha R, Butts C. L-BLP25: A peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007; 13: S4652-4654.
17. Evans C, Dalgleish AG, Kumar D. Review article: Immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006; 24: 1163-1177.
18. Heriot AG, Marriott JB, Cookson S et al. Reduction in cytokine production in colorectal cancer patients: Association with stage and reversal by resection. Br J Cancer 2000; 82: 1009-1012.
19. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 1999; 353: 345-350.
20. Peoples GE, Holmes JP, Hueman MT et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14: 797-803.